0001183740-21-000070.txt : 20210330 0001183740-21-000070.hdr.sgml : 20210330 20210329201029 ACCESSION NUMBER: 0001183740-21-000070 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210330 DATE AS OF CHANGE: 20210329 EFFECTIVENESS DATE: 20210330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProMIS Neurosciences Inc. CENTRAL INDEX KEY: 0001374339 IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-393944 FILM NUMBER: 21783256 BUSINESS ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 BUSINESS PHONE: 416-847-6898 MAIL ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 FORMER COMPANY: FORMER CONFORMED NAME: AMORFIX LIFE SCIENCES LTD DATE OF NAME CHANGE: 20060831 D 1 primary_doc.xml X0708 D LIVE 0001374339 ProMIS Neurosciences Inc. SUITE 200, 1920 YONGE STREET TORONTO A6 ONTARIO, CANADA M4S 3E2 415-341-5783 CANADA (FEDERAL LEVEL) AMORFIX LIFE SCIENCES LTD Corporation true Elliot Goldstein SUITE 200, 1920 YONGE STREET TORONTO A6 ONTARIO, CANADA M4S 3E2 Executive Officer Director Eugene Williams Suite 200, 1920 Yonge Street Toronto A6 ONTARIO, CANADA M4S 3E2 Executive Officer Director William Wyman Suite 200, 1920 Yonge Street Toronto A6 ONTARIO, CANADA M4S 3E2 Director Patrick Kirwin SUITE 200, 1920 YONGE STREET TORONTO A6 ONTARIO, CANADA M4S 3E2 Director Neil Cashman SUITE 200, 1920 YONGE STREET TORONTO A6 ONTARIO, CANADA M4S 3E2 Executive Officer Director Richard Gregory SUITE 200, 1920 YONGE STREET TORONTO A6 ONTARIO, CANADA M4S 3E2 Director Steven Plotkin SUITE 200, 1920 YONGE STREET TORONTO A6 ONTARIO, CANADA M4S 3E2 Executive Officer Daniel E. Geffken SUITE 200, 1920 YONGE STREET TORONTO A6 ONTARIO, CANADA M4S 3E2 Executive Officer Johanne Kaplan SUITE 200, 1920 YONGE STREET TORONTO A6 ONTARIO, CANADA M4S 3E2 Executive Officer Biotechnology Decline to Disclose 06b false 2021-03-22 false true true true true true 1% convertible debentures, payable annually. The Convertible Debentures will mature on March 22, 2026 and are convertible into shares at US$0.10 per share. false 0 7000000 7000000 0 Total Offering Amount represents principal amount of US$7,000,000 convertible debentures. There is no guarantee that the convertible debentures will be converted into shares. false 7 0 0 0 false ProMIS Neurosciences Inc. /s/ Elliot Goldstein Elliot Goldstein CEO and President 2021-03-29